Novartis International AG / Nine new analyses show Novartis' LCZ696 could
change course of heart failure for patients[1],[2] . Processed and transmitted
by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
o New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths,
emergency room visits, hospitalizations, worsening symptoms and need for
more intense treatment in HFrEF patients versus enalapril[1]
o Patients' and doctors' assessments of disease severity were also
significantly better with LCZ696 than enalapril[1]
o Effects on certain heart biomarkers indicate that compared to enalapril,
LCZ696 reduced cardiac stress and damage[1]
o Heart failure is highly debilitating and life-threatening - up to half of
patients who die from cardiovascular causes will die suddenly when their
heart stops pumping, before medical intervention is possible[2],[3]
Basel, November 17, 2014 - New data on Novartis' investigational medicine,
LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF)
shows it has the potential to change the course of the disease for
patients[1],[2]. In August 2014 Novartis presented topline results from the
landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor
enalapril on key endpoints, including significantly reducing the risk of CV
death or heart failure hospitalization[4].
The new analyses being presented for the first time at the American Heart
Association Scientific Sessions 2014, with a paper being simultaneously
published in Circulation, show that versus enalapril, LCZ696
significantly[1],[2]:
o reduced the risk of dying suddenly by 20%[2] - in HFrEF patients 45% of CV
deaths and 36% of all cause deaths are sudden[2]
o reduced first and subsequent HFrEF hospitalizations by 21% and 23%
respectively[1]
o reduced hospitalizations for a cardiovascular reason or for any reason
both by 16%[1]
o reduced the need for more intense treatment at home by 16%[1]
o reduced emergency room visits because of rapid symptom worsening by 30%[1]
When hospitalized, LCZ696 and enalapril patients remained under care for
approximately the same time, but those on LCZ696 had 18% fewer stays in
intensive care and were 31% less likely to need IV drugs to help their heart
pump. Patients' reports of how well they felt and doctors' assessments of
disease severity were also significantly better with LCZ696 than enalapril[1].
"These results provide strong evidence that we may be able to do more than
reduce risk of death or hospitalization with LCZ696 versus enalapril. This
therapy offers hope to millions of people living with HFrEF that they can also
reduce or slow the decline in their heart function, potentially altering the
progression of their disease," said David Epstein, Division Head, Novartis
Pharmaceuticals.
Analysis of cardiac biomarkers (NTpro-BNP and troponin), substances that
indicate the progression of cardiac disease and risk, showed levels were
consistently lower with LCZ696 than enalapril, reflecting reduced heart stress
and subsequent damage[1],[2].
LCZ696, a twice a day medicine being investigated for heart failure, acts to
enhance the protective neurohormonal systems of the heart (NP system) while
simultaneously suppressing the harmful system (the RAAS). Currently available
medicines for HFrEF only block the harmful effects and mortality remains very
high with up to 50% of patients dying within 5 years of a diagnosis of heart
failure[4],[5],[6].
Novartis plans to complete the file for marketing authorization with the US
FDA by the end of 2014 and in the European Union in early 2015.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in